Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL-10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells  by Foley, Jason E. et al.
Biology of Blood and Marrow Transplantation 14:959-972 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1409-0001$32.00/0
doi:10.1016/j.bbmt.2008.06.007Th2 Cell Therapy of Established Acute Graft-Versus-
Host Disease Requires IL-4 and IL-10 and Is Abrogated
by IL-2 or Host-Type Antigen-Presenting Cells
Jason E. Foley,1 Jacopo Mariotti,1 Kaitlyn Ryan,1 Michael Eckhaus,2 Daniel H. Fowler1
1Center for Cancer Research, National Institutes of Health, Experimental Transplantation and Immunology Branch;
Bethesda, Maryland; and 2National Center for Research Resources, National Institutes of Health, Bethesda, Maryland
Correspondence and reprint requests: Daniel H. Fowler, MD, National Institutes of Health, 10 Center Drive, Building
10, CRC, 3 EAST Labs, 3-3330, Bethesda, MD 20892 (e-mail: dhfowler@helix.nih.gov).
Received April 25, 2008; accepted June 6, 2008
ABSTRACT
Delayed donor Th2 cell infusion permits a graft-versus-tumor (GVT) effect to occur with subsequent amelio-
ration of established graft-versus-host disease (GVHD). Relative to GVHD controls (B6-into-BALB/c model),
recipients of delayed Th2 cells (day 14 post-BMT) had increased survival (3/3 experiments [exp]; each exp P\
.0001) and reduced GVHD by histology analysis 5 days post-Th2 infusion without increased tumor burden (3 of
3 exp; each exp P# .02). Th2 cell-mediated amelioration of GVHDwas associated with greatly reduced allospe-
cific IFN-g secretion, in vivo augmentation of allospecific IL-4 and IL-10 secretion, and reduction in donor
CD81 T cell number post-BMT (3 of 3 exp; each comparison, P # .003). To better understand the molecular
mechanism of this GVHD therapy, Th2 cells were generated from wild-type (WT), IL-4 deficient (KO), or
IL-10 KO donors: remarkably, recipients of IL-4 or IL-10 KOTh2 cells had no survival advantage, no improve-
ment in GVHDby histology, no reduction in CD81T cell expansion post-BMT, and no in vivo shift toward type
II cytokines. We reasoned that IL-2 and alloantigen availability may be limiting factors for Th2 cell therapy, and
as such, evaluated whether coadministration of IL-2 or coinfusion of host-type antigen-presenting cells (APC)
might intensify the anti-GVHD effect. However, contrary to these hypotheses, concomitant IL-2 therapy or
APC administration fully abrogated the Th2 cell-mediated survival advantage and histology-defined GVHD re-
duction, reduced Th2 cell expansion in vivo while promoting CD81T cell expansion from cells originating from
the initial allograft, and impaired type II polarization in vivo. In conclusion, Th2 cell therapy can rapidly amelio-
rate severe GVHD via IL-4 and IL-10 mediated mechanisms, and potentially, via IL-2 consumption and APC
modulation mechanisms.
 2008 American Society for Blood and Marrow Transplantation
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The separation of graft-versus-leukemia (GVL)
and graft-versus-tumor (GVT) effects from graft-
versus-host disease (GVHD) can be difficult because
of their shared biology [1]. Experiments that evaluated
the Th1/Th2 cellular balance in the allograft exemplify
this conclusion; that is, CD41Th2 and CD81Tc2 cells,
mediated reduced GVHD relative to Th1/Tc1 cells or
unmanipulated T cells [2,3], but were also associated
with reduced GVL [4,5] and GVT [6] effects. To sepa-
rate GVT effects from GVHD on a temporal basis, we
developed an effective therapeutic strategy whereby an
in vivo Th1/Tc1 response (generated by infusion ofunmanipulated donor T cells) was followed by delayed
administration of rapamycin-exposed donor Th2 cells
[7]. In the current project, our primary objectives were
to (1) perform mechanistic studies to better understand
Th2 cell therapy of established GVHD, and (2) test
therapeutic interventions that might enhance this
therapy.
In our previous study [7], we found that prevention
of GVHDwas dependent upon Th2 cell production of
the cytokine responsible for type II cytokine skewing,
IL-4 [8]. In the current study, we evaluated whether
Th2 cell therapy of 14-day established GVHD was
also dependent upon IL-4. There is currently no data959
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treatment of established GVHD. Previous in vitro
data are somewhat disparate relative to the capacity
of IL-4 to modulate established effector T cell re-
sponses. It has been shown that effector Th1 cells
are relatively resistant to the polarizing effect of
IL-4 [9], and as such, it is possible that IL-4 may
not play a role in the therapy of established GVHD.
On the other hand, others found that IL-4 inhibited
effector Th1/Tc1 cells [10], and as such, we reasoned
that Th2 cell IL-4 secretion might indeed counteract
established GVHD.
We also evaluated whether IL-10may represent an
effector mechanism for Th2 cell therapy of GVHD.
High levels of IL-10 after clinical HLA-mismatched
transplantation were associated with immune toler-
ance [11]; furthermore, recipient IL-10 polymor-
phisms confer significant protection against the
development of severe clinical acute GVHD [12].
However, initial murine studies found that IL-10
administration did not reduce acuteGVHD (aGVHD)
in models involving transplantation across minor [13]
or major [14] histocompatibility barriers. The role of
IL-10 in GVHD prevention was nonetheless con-
firmed in a subsequent murine study that found
IL-10-deficient T cells to yield increased GVHD and
identified low-dose, but not high-dose, IL-10 adminis-
tration as an approach to prevent CD4- and CD8-
mediated GVHD [15]. IL-10 also contributes to the
ability of adoptively transferred regulatory T cells
[16,17], donor antigen-presenting cells (APC) [18],
or host APC [19] to prevent murine GVHD. Further-
more, IL-10 transduction of donor mesenchymal stem
cells conferred protection against murine GVHD [20];
and finally, inhibition of alloreactivity by type I regula-
tory T cells appears to involve IL-10 production, with
no known contribution from IL-4 [21]. Although these
multiple lines of experimentation clearly indicate that
IL-10 plays a role in GVHD prevention, the role of
IL-10 in the treatment of established GVHD has
not been previously characterized. However, IL-10
contributes to the modulation of ongoing immune dis-
eases such as autoimmune encephalomyelitis [22], and
as such, we hypothesized that Th2 cell production of
IL-10 would contribute to the therapy of established
GVHD.
In addition, we evaluated 2 potential approaches to
enhance the therapeutic efficacy of Th2 cell treatment
of GVHD. First, we tested whether IL-2 administra-
tion after Th2 cell infusion would enhance the anti-
GVHD effect. IL-2 administration is thought to
enhance the efficacy of adoptive T cell therapy in the
syngeneic setting [23], presumably in part because ex
vivo expanded effector T cells are predominately IL-
2 dependent [24,25]; this biology may be particularly
relevant to Th2 cell therapy in light of this popula-
tion’s requirement for IL-2/STAT5 signaling in theface of their negligible IL-2 production [26]. Given
this information, we hypothesized that IL-2 therapy
post-Th2 cell infusion would improve the therapy of
established GVHD. On the other hand, it is possible
that IL-2 infusion may abrogate Th2 cell therapy:
that is, IL-2 contributes to the initial afferent stages
of murine GVHD [27,28], and to some extent to the
efferent stages of GVHD, as evidenced by the efficacy
of anti-IL-2 therapy in the treatment of established
clinical GVHD [29].
Second, we reasoned that Th2 cell therapy of
established GVHD might be augmented by the infu-
sion of host-type APC. That is, the Th2 cell product
is generated by a costimulation method that yields
a polyclonal T cell receptor repertoire [30], and as
such, Th2 cell activation in vivo occurs by allosensiti-
zation [6]. Host APC present at the time of condition-
ing induce donor T cell alloreactivity [31]; however,
such host APC are eventually replaced with donor
APC posttransplant, and as such, delay in administra-
tion of donor lymphocytes results in reduced alloreac-
tivity [32]. As such, we hypothesized that delayed
administration of host APC may enhance the in vivo
activation of the Th2 cell product, thereby improving
the anti-GVHD effect.
MATERIALS AND METHODS
Animals
BALB/c (H-2Kd) were utilized as hosts, whereas
C57Bl/6 (H-2Kb), Ly5.1 congenic (H-2Kb), and
Thy1.1 congenic (CD90.11; H-2Kb) mice were uti-
lized as sources of donor cells; these mice were
obtained from Frederick Cancer Research Facility
(Frederick, MD). B6 mice genetically deficient in IL-
4 or IL-10 production were purchased from The Jack-
son Laboratory (Bar Harbor, ME). All mice were 6 to
12 weeks old, maintained in a specific pathogen-free
facility at theNational Institutes ofHealth, and treated
according to an approved animal protocol.
Ex Vivo Generation of Donor Th2 Cells and Donor
and Host APC
Spleen cells from donor mice were harvested and
RBCwere lysed using ACK buffer (Quality Biological,
Inc., Gaithersburg, MD). B cells were depleted using
goat antimouse conjugated magnetic bioparticles (Pol-
ysciences Inc., Warrington, PA), and CD8 cells were
depleted (CD4 cell enrichment kit, Stem Cell Tech-
nologies, Vancouver, CA). To generate CD3, CD28
mAb coated beads, M450 Dynabeads (Dynal ASA,
Oslo, Norway) were incubated with antimurine CD3
and CD28 mAbs (BD PharMingen, San Diego, CA)
in 0.1 M-borate solution at 37C overnight as
described previously [33]. CD3, CD28 mAb-coated
beads were then washed with PBS containing 3%
FBS (Gemini Bio-Products, Woodland, CA), 5 mM
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azide (Sigma, St. Louis, MO), and brought up in the
same solution at a concentration of 40  106 beads/
mL. Th2 cells were generated using CD3/CD28-
coated beads in RPMI complete media with rhIL-2
(20 IU/mL), rhIL-7 (20 ng/mL), rmIL-4 (1000 IU/
mL; all cytokines from Peprotech, Rocky Hill, NJ), ra-
pamycin (10 mM; LC Laboratories, Woburn, MA),
and 3.3 mMN-acetyl-cysteine (Bristol-Myers Squibb;
Princeton, NJ). Specific cytokine-containing complete
media was added to the Th2 cultures daily from days 2
to 6 to maintain a cell concentration between 0.2 and
1.0 106 cells/mL; Th2 cells were harvested for adop-
tive transfer experiments on day 6 of culture.
To generate APC for in vitro supernatant genera-
tion and for adoptive transfer experiments, donor-type
B6 or host-type BALB/c bone marrow cells were cul-
tured for 6 days in rmGM-CSF and rmIL-4 (each at
1000 IU/mL; PeproTech). Bacterial LPS (1 mg/mL;
Calbiochem, San Diego, CA) was added to the final
24 hours of culture.
Bone Marrow Transplantation (BMT) and Tumor
Cell Inoculation
BALB/c mice were lethally irradiated (850 cGy;
137Cs g-irradiation source; Gamma Cell 40; Atomic
Energy of Canada, Ottawa, Canada) and reconsti-
tuted by intravenous (i.v.) injection of B6 bone mar-
row (10  106 cells). To maintain continuity with
our previous experiments [6,7,34] and to enable tu-
mor burden as an endpoint for histology studies, all
cohorts except for an engraftment control cohort re-
ceived host-type mammary carcinoma cells (TS/A
cell line [35]; 0.1  106 cells by i.v. injection). One
treatment group received only BMT and TS/A cells
(‘‘tumor control cohort’’). Another treatment group
received BMT, TS/A cells, and additional donor
splenic T cells enriched by B cell depletion (i.v. injec-
tion of 5 or 20  106 T cells, dose specified in table
footnotes; ‘‘GVHD control cohort’’). As per our an-
imal protocol, any transplant recipient that was pre-
morbid (as defined by .20% loss in body weight,
severe loss in activity, or pulmonary compromise)
was euthanized. Lethality in the GVHD control co-
hort was approximately 50% by day 14 posttrans-
plant; at this time point, surviving recipients were
randomized to receive no further therapy (that is,
maintained as a GVHD control) or further day 14
therapy with donor Th2 cells (10  106 cells by i.v.
injection). For post-BMT IL-2 administration, mice
received day 14 to day 18 therapy with an intermedi-
ate dose of IL-2 that we have previously utilized [36]
(50,000 IU by i.p. injection, twice daily). For APC
injection, mice received 10  106 cells by i.v. injec-
tion at day 14 post-BMT (just prior to Th2 cell
infusion).Histology
Mice from each cohort in each of the 3 transplant
experiments were evaluated at day 19 post-BMT.
Liver, stomach, small intestine, large intestine, ce-
cum, and skin were harvested for GVHD score;
lung was harvested for evaluation of tumor burden.
Tissues were fixed in formaldehyde and stained with
hematoxylin and eosin. GVHD severity score ranged
from 0 to 4, where 0 was assigned as normal and 4 as
maximal level of GVHD. Each organ was scored sep-
arately, yielding a maximum cumulative GVHD
score of 24. Semiquantitative determination of tumor
burden was scored on a scale of 0 to 4: 0 5 no tumor
cells identified; 1 5 \10% of lung involved with
tumor; 2 5 10%-20% lung involvement; 3 5 21%-
30% lung involvement; and 4 5 .30% lung involve-
ment. Scoring of GVHD and tumor burden was
performed by a pathologist (M.A.E.) in a blinded
fashion.
Flow Cytometry for Cell Surface Markers
Three-color flow cytometry was performed
(FACSCalibur instrument and CellQuest software;
BD Biosciences, San Jose, CA). Live events (5000-
10,000) were acquired, with propidium iodide
exclusion of dead cells. To facilitate cell tracking
post-BMT, Th2 cells were generated from Thy1.1
congenic mice, and unmanipulated donor splenic T
cells were isolated from Ly5.1 congenic mice. Spleens
were harvested at day 19 post-BMT, and single-cell
suspensions were labeled with Abs against murine
CD4, CD8, CD19, Ly5.1, or CD90.1 (anti-Thy1.1)
conjugated with FITC, PE, or allophycocyanin (all ob-
tained from BD PharMingen).
Determination of Post-BMT Cytokine Phenotype
Spleen cells were collected post-BMT and sub-
jected to no stimulation, and B6 (syngeneic) and
BALB/c (allogeneic) APC stimulation. Spleen cells
were plated at 0.5  106 cells/mL; APC were utilized
at a spleen cell to APC ratio of 10:1. After 24 hours,
supernatants were collected and analyzed for cytokine
content (IL-2, IL-4, IL-10, and IFN-g) by Bio-Plex
multiplex sandwich immunoassay (Bio-Rad, Hercules,
CA).
Statistics
Survival analysis was performed using Kaplan-
Meier survival curves and a log-rank test. For survival
analyses involving day 14 post-BMTTh2 cell therapy,
deaths through day 14 (prior to randomization) were
censored out. For small sample size comparison, a Stu-
dent’s t-test was used. Comparison values of P\ .05
were considered statistically significant.
962 J. E. Foley et al.Table 1. Th2 Cell IL-4 and IL-10 Production Contributes to Prolongation of Survival Time During GVHD
Transplant Componentsb
Cohort # Host Tumora BM T Cells Th2 Cells Days of Post-BMT Survivalc P-valuesd
1 2 1 2 2 35 (35-35)
2 1 1 2 2 21 (21-23)
3 1 1 1 2 27 (25-29)
4 1 1 1 Th2 (WT) 34 (34-35) \.0001 (#4 vs. #3)
5 1 1 1 Th2 (IL-4KO) 29 (28-30) NS (#5 vs. #3)
6 1 1 1 Th2 (IL-10KO) 23 (21-24) NS (#6 vs. #3)
aBALB/c hosts received 850 cGy XRT and host-type TS/A tumor cells (0.1  106 cells).
bC57BL/6-into-BALB/c (day 0); BM (C57BL/6; 10 106 cells); donor T cells (20 106 cells); donor Th2 cells (WT, IL-4 KO, IL-10KO; 10
106 cells; day 14 post-BMT).
cMedian and range values for number of days of posttransplant survival; n 5 7/group.
dUnpaired t-test.RESULTS
IL-4 and IL-10 Contribute to Th2 Cell Therapy of
Established GVHD: Survival
Using a model of a 14-day established acute
GVHD, we first evaluated (Experiment 1) the effect
of wild-type (WT), IL-4-deficient (KO), or IL-10
KO Th2 cells on post-BMT survival (Table 1). All en-
graftment control recipients (cohort 1) survived post-
BMT. Tumor control recipients (cohort 2) that did
not receive donor T cells in conjunction with the
BMT died from systemic malignancy (as evidenced
by pulmonary compromise) at a median of 21 days
post-BMT (range: 21-23 days). Additional cohorts re-
ceived tumor cells and BMT augmented with donor T
cells; severe aGVHD occurred in this cohort, as
approximately 50% of recipients died by day 14 post-
transplant. At day 14 post-BMT, surviving recipients
in this cohort were randomized to receive no further
therapy or further therapywithTh2 cells. Subjects ran-
domized to no further therapy (cohort 3) had a median
survival of 27 days (range: 25-29 days); death in this co-
hortwas primarily attributable toGVHDbecause of an
absence of pulmonary compromise, the presence of
clinical GVHD (hunched posture, diarrhea), and evi-
dence of severe GVHD by histology (see Figure 1).
Recipients of T cell-containing allografts that were
randomized to receive WT donor Th2 cells on day 14
post-BMT (cohort 4) had increased survival time rela-
tive to the GVHD control cohort (median survival of
34 days [range: 34-35 days]; P\ .0001); death in this
cohort was primarily attributable to GVHD because
pulmonary compromise was not apparent and clinical
GVHD was apparent. The ameliorating effect of
delayed Th2 cell infusion was abrogated if the Th2
cells were deficient in IL-4 production (cohort 5; me-
dian survival time of 29 days [range: 28-30 days]; not
increased relative to GVHD controls) or deficient in
IL-10 production (cohort 6; median survival time of
23 days [range: 21-24 days]; not increased relative to
GVHD controls).Effect ofWT, IL-4, or IL-10 KOTh2 Cells on GVHD
and Tumor Burden: Histology
In Experiment 1, in addition to the survival analy-
sis, recipients from each cohort were evaluated for
signs of GVHD and tumor by histology at day 19
post-BMT (5 days post-Th2 cell infusion). Recipients
of Th2 cells had significantly reduced GVHD relative
to the GVHD control cohort (Figure 1; median
GVHD score reduced from 10.0 to 6.0, P 5 .0002)
without a significant increase in tumor burden. The
anti-GVHD effect of the Th2 cell therapy was
reflected across all tissues examined. For example, in
this experiment, mean liver GVHD score was reduced
from 2.0 (GVHD controls) to 1.1 (Th2 cell recipients;
P 5 .001), mean large intestine GVHD score was re-
duced from 2.3 to 1.0 (P 5 .004), and mean skin
GVHD score was reduced from 1.4 to 1.0 (P 5 .07).
In marked contrast, recipients of IL-4 KO and IL-10
KO Th2 cells did not have reduced GVHD by histol-
ogy (median scores, 10.4 and 10.6, respectively).
Delayed Th2 Cell Infusion Inhibits Post-BMT Type I
Cytokines in an IL-4 and IL-10-Dependent Manner
In Experiment 1, the T cell cytokine phenotype
was determined at day 19 post-BMT to further charac-
terize the immune modulation effects and cytokine
dependence of delayed Th2 cell infusion (Table 2).
As anticipated, T cells from engraftment and tumor
controls (cohorts 1 and 2) had nominal post-BMT se-
cretion of type I or type II cytokines in response to sec-
ondary in vitro allostimulation. Also as anticipated, T
cells from GVHD controls (cohort 3) predominately
secreted increased IFN-g in response to alloantigen.
As such, GVHD in this model was most consistent
with a type I cytokine phenotype.
Infusion of Th2 cells at day 14 post-BMT resulted
in an approximate 10-fold increase in the capacity of
posttransplant T cells to produce the type II cytokines
IL-4 and IL-10 upon alloantigen restimulation (co-
hort 4). Concomitantly, such Th2 recipients had
significantly reduced secretion of IFN-g relative to the
GVHD cohort (reduction from a median value of 249
to 48 pg/mL, P5 .0002). Th2 cell deficiency of either
IL-4 (cohort 5) or IL-10 (cohort 6) significantly
reduced the capacity of Th2 cells to promote both
IL-4 and IL-10 secretion post-BMT, and completely
abrogated the ability of the delayed Th2 cell infusion
to inhibit IFN-g secretion post-BMT.
Delayed Th2 Cell Infusion Restricts the Number of
Donor CD81 T Cells Post-BMT
Utilizing these day 19 post-BMTcohorts, we char-
acterized the effect of delayed Th2 cell infusion on the
in vivo expansion of T cells contained in the initial
transplant inoculum (Figure 2). In Experiment 1, the
congenic donor strain was not available, and as such,
we could not differentiate the post-BMT contribution
of Th2 cells fromCD41T cells contained in the initial
allograft. Relative to GVHD controls, recipients of
delayed WT Th2 cells had significantly increased
Figure 1. Delayed administration of Th2 cells improves balance of
GVHD and GVT effects. B6-into-BALB/c BMT was performed
(850 cGy host irradiation). Cohorts received donor marrow alone
(‘‘BMT’’); marrow and host-type TS/A tumor cells (‘‘TSA’’); or mar-
row, tumor cells, and additional donorT cells (‘‘GVHD’’). Other co-
horts received marrow, tumor cells, donor T cells, and additional
donor CD41 Th2 cells generated ex vivo in high-dose rapamycin
(10 mM; administered on day 14 post-BMT); Th2 cells were gener-
ated from either wild-type donors (‘‘Th2’’) or IL-4-deficient donors
(‘‘Th2 42/2’’) or IL-10-deficient donors (‘‘Th2 102/2’’). On day 19
post-BMT, lungs from treatment cohorts were removed to evaluate
tumor burden; liver, stomach, small intestine, large intestine, cecum,
and skin were harvested to assess GVHD. (A) For GVHD, each or-
gan was scored on a scale of 0 to 4, with cumulative GVHD severity
score shown (maximum value 5 24). (B) For tumor burden, a semi-
quantitative determination of tumor cell infiltration was scored on
a scale of 0 to 4; n 5 7 subjects were evaluated in each cohort.
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964 J. E. Foley et al.Figure 2. Donor Th2 cells inhibit donor CD81 T cell expansion after allogeneic BMT. B6-into-BALB/c BMT was performed (850 cGy host
irradiation). Cohorts received donor marrow alone (‘‘BMT’’); marrow and TS/A tumor cells (‘‘TSA’’); or marrow, tumor cells, and additional
donor T cells (‘‘GVHD’’). Other cohorts received marrow, tumor cells, donor T cells, and additional donor CD41 Th2 cells generated from
either wild-type donors (‘‘Th2’’) or IL-4 deficient donors (‘‘Th2 42/2’’) or IL-10 deficient donors (‘‘Th2 102/2’’). On day 19 post-BMT, spleen
cells were isolated and the absolute number of donor CD81T cells (A) and CD41T cells (B) were calculated from flow cytometry data (cells per
spleen, 106). Data shown are mean 6 SEM (n 5 7 per cohort).post-BMT total CD41T cells (median value increased
from 3.1 to 6.2 106 CD4 cells per spleen, P5 .0010);
this CD4 cell increase was abrogated if the Th2 cell
product was deficient in IL-4 or IL-10 (Figure 2b).
Relative to GVHD controls, recipients of delayed
WT Th2 cells had significantly reduced numbers of
donor CD81T cells post-BMT (median value reduced
from 5.5 to 2.6 106 CD8 cells per spleen, P5 .0018).
Interestingly, Th2 cells deficient in IL-4 or IL-10 were
competent in their ability to prevent CD81 T cell
expansion post-BMT (Figure 2a).
Th2 Cell Therapy of Established GVHD is
Abrogated by IL-2 Administration
InExperiment 2, we next tested our hypothesis that
IL-2 administration would enhance the in vivo efficacy
ofTh2 cells. In this experiment (Table 3), GVHDcon-
trols (cohort 3) had increased survival time relative to
tumor controls (cohort 2), with an increase in survival
time from a median of 23 days post-BMT (range: 22-
26) to 33 days post-BMT (range: 31-35) until death
that occurred in the setting of clinical GVHD.Relative
to GVHD controls, delayed Th2 cell infusion resulted
in a further extension of survival time (increase in
median survival to 42 days post-BMT (range: 40-43;
P\ .0001). Contrary to our hypothesis, IL-2 adminis-
tration completely abrogated the extension of survival
time conferred by Th2 cells (cohort 6; median survival
reduced from 42 days post-BMT to 33 days post-BMT
[range: 31-36]; P\ .0001). A control group that re-
ceived additional therapy with IL-2 without Th2 cells
(cohort 4) had a trend towards modestly increased le-
thality relative to GVHD controls that did not receive
IL-2 (median survival reduced from 33 days post-BMT
to 31 days post-BMT [range: 27-32]; p 5 .0684).
IL-2 Reverses Th2 Cell Therapy of Established
GVHD: Histology
In Experiment 2, mice from each cohort were eval-
uated at day 19 post-BMT to characterize the effect ofday 14 Th2 cell infusion with or without IL-2 therapy
on GVHD and tumor burden as defined by histology
(Figure 3). Consistent with the survival data, Th2
cell recipients had reduced GVHD relative to
GVHD controls (average GVHD score reduced
from 10.0 to 5.6, P 5 .002). Similar to Experiment 1,
the anti-GVHD effect of Th2 cells was generally re-
flected across the different tissue sites evaluated:
mean liver score was reduced from 2.2 to 0.8 (P 5
.001), mean large intestine score was reduced form
1.4 to 0.6 (P5 .049), and mean skin score was reduced
from 1.2 to 1.0 (P 5 NS). Remarkably, the Th2 cell-
mediated improvement in GVHD was completely re-
versed by IL-2 therapy (average GVHD score in this
cohort, 10.0). IL-2 administration also increased
GVHD in the control cohort (average GVHD score,
14.2; increased relative to GVHD controls that did
not receive IL-2, P5 .0034). Each of the treatment co-
horts that received T cell-replete BMT with or with-
out Th2 cells and with or without IL-2 had reduced
tumor burden relative to tumor controls (Figure 3b).
IL-2 Reverses Th2 Cell Therapy of GVHD: Post-
BMT Cytokine Phenotype
In addition to histology studies, day 19 post-BMT
cohorts from Experiment 2 were evaluated for T cell
cytokine phenotype (Table 4). Post-BMT T cells
from GVHD controls had a high level of allospecific
IFN-g secretion (cohort 3; median value of 2196 pg/
mL) with nominal secretion of IL-4 or IL-10. Consis-
tent with our initial results, day 14 infusion ofTh2 cells
resulted in a near complete downregulation of IFN-g
secretion (median value reduced from 2196 to 81 pg/
mL,P\.0001) and an approximate 1- to 2-log increase
in IL-4 and IL-10 secretion (to median values of 3501
and 707 pg/mL, respectively). Remarkably, adminis-
tration of IL-2 after Th2 cell therapy tempered both
the observed downregulation in IFN-g (median value,
320 pg/mL,P5 .042) and the observed upregulation of
IL-4 (median value, 1117 pg/mL,P\.0001) and IL-10
Conditions for Th2 Cell Therapy of Established GVHD 965Table 3. Th2 Cell-Mediated Prolongation of Survival Time is Abrogated by IL-2 Therapy
Transplant Componentsb
Cohort # Host Tumora BM T Cells Th2 Cells rhIL-2 Injectionc Days of Post-BMT Survivald P-Valuese
1 2 1 2 2 2 43 (43-43)
2 1 1 2 2 2 23 (22-26)
3 1 1 1 2 2 33 (31-35)
4 1 1 1 2 1 31 (27-32) NS (#4 vs. #3)
5 1 1 1 Th2 (WT) 2 42 (40-43) \.0001 (#5 vs. #3)
6 1 1 1 Th2 (WT) 1 33 (31-36) NS (#6 vs. #3)
aBALB/c hosts received 850 cGy XRT and host-type TS/A tumor cells (0.1  106 cells).
bC57BL/6-into-BALB/c (day 0); BM (C57BL/6; 10 106 cells); donor T cells (20 106 cells); donorTh2 cells (WT; 10 106 cells; day 14 post-
BMT).
crhIL-2 50,000 IU/mouse 2/day I.P. for 5 days beginning at day 14 post-BMT.
dMedian and range for number of days of posttransplant survival; n 5 7/group.
eUnpaired t-test.(median value, 288 pg/mL, P5 .0002). In marked con-
trast to these relatively dramatic effects of IL-2 therapy
in the setting of Th2 cell infusion, IL-2 therapy did not
greatly modulate the post-BMTcytokine phenotype in
GVHD controls (cohort 4).
Figure 3. In vivo IL-2 administration abrogates Th2 cell therapy:
histology analysis. B6-into-BALB/c BMT was performed (850 cGy
host irradiation). Cohorts received donor marrow alone (‘‘BMT’’);
marrow andTS/A tumor cells (‘‘TSA’’); marrow, tumor cells, and ad-
ditional donor T cells (‘‘GVHD’’); or marrow, tumor cells, donor T
cells, and IL-2 therapy (‘‘GVHD1IL-2’’; 50,000 I.U., twice a day
from day 14 to day 18 post-BMT). Other cohorts received marrow,
tumor cells, donor T cells, and donor Th2 cells on day 14 post-BMT
either alone (‘‘Th2’’) or with IL-2 infusion (‘‘Th21IL-2’’). On day 19
post-BMT, lungs from treatment cohorts were removed to evaluate
tumor burden; liver, stomach, small intestine, large intestine, cecum,
and skin were harvested to assess GVHD. (A) For GVHD, each or-
gan was scored on a scale of 0 to 4, with cumulative GVHD score
shown (maximum value5 24). (B) For tumor burden, a semiquanti-
tative determination of tumor cell infiltration was scored on a scale of
0 to 4; n 5 5 subjects were evaluated per cohort.IL-2 Reverses Th2 Cell Therapy of GVHD: Donor T
Cell Tracking
In Experiment 2, donor Th2 cells were generated
from mice expressing the CD90.1 congenic marker.
As such, we were able to track the Th2 cell product
and evaluate the effect of Th2 cells on donor CD41
and CD81 T cells in the allograft. First, and perhaps
most importantly, we found that IL-2 therapy reduced
the number of Th2 cells present at day 19 post-BMT
(Figure 4c; median Th2 cell number reduced from
7.3 to 3.9  106 cells per spleen, P 5 .0003).
Relative to the GVHD control cohort, delayed
administration of donor Th2 cells did not reduce the
number of post-BMT CD41 T cells emanating from
the initial allograft (Figure 4b; median values of 16.6
and 18.1  106 cells/spleen; p 5 NS). Interestingly,
in marked contrast to the inhibitory effect of IL-2 on
in vivo Th2 cell expansion, IL-2 therapy increased
the number CD4 cells emanating from the initial allo-
graft whether such T cells were administered with Th2
cells (Figure 4b; increase in median CD4 number from
16.6 to 26.6  106 cells/spleen, P 5 .0048) or without
Th2 cells (Figure 4b; increase in median CD4 number
from 18.1 to 26.1  106 cells/spleen, P 5 .0084).
Similar to our previous results (Figure 2), Th2 cell
infusion significantly reduced the post-BMT number
of donor CD81 T cells relative to GVHD controls
(Figure 4a; median values reduced from 31.1 to 15.9 
106 cells/spleen, P5 .0010). Th2 cell-mediated restric-
tion of CD81T cell expansionwas partially reversed by
IL-2 administration (increase in median CD8 number
from 15.9 to 23.9  106 cells/spleen, P 5 .0310). IL-2
administration did not significantly increase the num-
ber of posttransplant CD8 cells in GVHD controls (in-
crease from 31.1 to 36.2  106 cells/spleen, P5NS).
Th2 Cell Therapy of GVHD is Abrogated by
Adoptive Transfer of APC
In Experiment 3, we next tested our hypothesis
that a relative paucity of host APC may represent
966 J. E. Foley et al.T
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.a limiting factor to Th2 cell therapy of established
GVHD. In this experiment (Table 5), GVHD controls
(cohort 3) had an extension of survival time relative to
tumor controls (cohort 2; median 1 [range] survival
increased from 21 [range: 20-21] to 33 [range: 31-35]
days, P\ .0001). Similar to our previous experiments,
infusion of Th2 cells at day 14 post-BMT resulted in
an extension of survival time relative to GVHD con-
trols (median1 [range] survival increased to 45 [range:
42-46] days, P 5 .0001).
In GVHD controls, adoptive transfer of donor
APC (cohort 4) or host APC (cohort 5) did not greatly
Figure 4.Th2 cell inhibition of CD81T cell expansion is abrogated
by IL-2. B6-into-BALB/c BMT was performed (850 cGy host irra-
diation). Cohorts received donor marrow alone (‘‘BMT’’); marrow
and TS/A tumor cells (‘‘TSA’’); marrow, tumor cells, and additional
donorT cells (‘‘GVHD’’); or marrow, tumor cells, donorT cells, and
IL-2 therapy (‘‘GVHD1IL-2’’; 50,000 I.U., twice a day from day 14
to day 18 post-BMT). Other cohorts received marrow, tumor cells,
donor T cells, and donor Th2 cells on day 14 post-BMT either alone
(‘‘Th2’’) or with IL-2 infusion (‘‘Th21IL-2’’). On day 19 post-BMT,
spleen cells were isolated and the absolute number of donor CD81T
cells (A) and CD41 T cells (B) emanating from the initial allograft,
and the absolute number of CD90.11Th2 cells [C] were calculated
from flow cytometry data (cells per spleen, 106). Data shown are
mean 6 SEM (n 5 5 per cohort).
Conditions for Th2 Cell Therapy of Established GVHD 967Table 5. APC Adoptive Transfer Abrogates Th2 Cell Therapy of GVHD
Transplant Componentsb
Cohort # Host Tumora BM T Cells Th2 Cells Donor DCc Host DCd Days of Post-BMT Survivale P-Valuesf
1 2 1 2 2 46 (46-46)
2 1 1 2 2 21 (20-21)
3 1 1 1 2 33 (31-35) .0001 (#3 vs. #2)
4 1 1 1 2 1 32 (27-32) NS (#4 vs. #3)
5 1 1 1 2 2 1 32 (27-34) NS (#5 vs. #3)
6 1 1 1 Th2 2 2 45 (42-46) .0001 (#6 vs. #3)
7 1 1 1 Th2 1 2 34 (21-36) NS (#7 vs. #3)
8 1 1 1 Th2 2 1 25 (18-29) .02 (#8 vs. #3)
aBALB/c host received 850 cGy XRT; 0.1  106 host TS/A tumor.
bC57BL/6 into BALB/c (day 0); BM (C57BL/6; 10 106 cells); donor T cells (5 106 cells); donor Th2 cells (10 106 cells; day 14 post-BMT).
cFresh DC cells generated from donor C57BL/6 (10  106 cells; day 14 post-BMT).
dFresh DC cells generated from host BALB/c (10  106 cells; day 14 post-BMT.
eMedian and range of number of days of posttransplant survival; n 5 5/group.
fUnpaired t-test.alter posttransplant survival time (median 1 [range]
survival times of 33 [range: 31-35] days [without
APC infusion], 32 [range: 27-32] days [donor APC
infusion], and 32 [range: 27-34] days [host APC infu-
sion]). In marked contrast, in the setting of delayed
Th2 cell therapy, infusion of donor APC (cohort 7)
or host APC (cohort 8) completely abrogated the ex-
tension of survival time conferred by the Th2 cell pop-
ulation (median1 [range] survival times reduced to 34
[range: 21-36] days [donor APC infusion] and 25
[range: 18-29] days [host APC infusion]).
APC Transfer Abrogates Th2 Cell Therapy of
Established GVHD: Histology
In Experiment 3, similar to our prior results, Th2
cell recipients had reduced GVHD by histology rela-
tive to the GVHD control cohort (Figure 5a; average
GVHD score reduced from 7.4 to 5.0,P5 .02). Similar
toExperiments 1 and2,Th2 cellmodulation ofGVHD
was generally apparent across tissue sites evaluated.
Specifically, mean liver score was reduced from 0.6 to
0.4 (P 5 NS), mean large intestine score was reduced
from 2.2 to 1.0 (P5 .03), and mean skin GVHD score
was reduced from 1.6 to 0.8 (P5 .01). Remarkably, co-
infusionof host-typeAPCandTh2 cells completely ab-
rogated the Th2 cell anti-GVHD effect (average
GVHD score, 10.4); in the absence of Th2 cells, host
APC infusion also increased GVHD (average GVHD
score increased from 7.4 to 9.4). Infusion of donor-
type APC did not significantly alter GVHD scores
either in the presence or absence of Th2 cell infusion.
Each of the cohorts that received the T cell-replete
allograft had reduced tumor burden relative to the
tumor control cohort (Figure 5b).
APC Transfer Abrogates Th2 Cell Therapy of
GVHD: Cytokine Phenotype
Similar to our previous results, post-BMT T cells
from GVHD controls in Experiment 3 primarilysecreted IFN-g in an allospecific manner (Table 6, co-
hort 3; median value, 388 pg/mL). In GVHD controls,
the additional infusion of donor-type APC at day 14
posttransplant did not significantly alter IFN-g secre-
tion (cohort 4, median value, 328 pg/mL); in contrast,
additional infusion of host-type APC significantly
increased IFN-g secretion (cohort 5, median value,
812 pg/mL, P 5 .03).
Also consistent with our prior results, delayed
therapy with Th2 cells greatly reduced post-BMT
IFN-g secretion (median value decreased from 388
to 83 pg/mL, P 5 .0005) and greatly increased both
IL-4 secretion (median value increased from 67 to
497 pg/mL, P\ .0001) and IL-10 secretion (median
value increased from 26 to 160 pg/mL, P\ .0001). Co-
infusion of donor-type APC in addition to Th2 cells
tended to increase IFN-g secretion (median value in-
creased from 83 to 115 pg/mL, P 5 .07); by compari-
son, coinfusion of host-type APC in addition to Th2
cells significantly increased post-BMT IFN-g secre-
tion (median value increased from 83 to 279 pg/mL,
P \ .0004). Furthermore, coinfusion of donor- or
host-type APC tended to also reduce the Th2 cell-
mediated promotion of post-BMT IL-4 and IL-10
secretion.
APC Transfer Abrogates Th2 cell therapy of
GVHD: Donor T Cell Tracking
In Experiment #3, we tracked the Th2 cell product
in vivo using the CD90.1 marker and evaluated the ef-
fect of Th2 cells with or without coinfusion of donor
or host APC on donor CD41 and CD81 T cells ema-
nating from the allograft. First, we found that coinfu-
sion of host-type APC, but not donor-type APC,
significantly reduced the number of Th2 cells present
in vivo at day 19 post-BMT (Figure 6c; median Th2
cell number reduced from 16.6 to 5.4  106 cells per
spleen, P\ .0001). Second, similar to our prior results,
we found that Th2 cell therapy did not significantly
968 J. E. Foley et al.Figure 5.Host-type APC infusion abrogates Th2 cell anti-GVHD effect: histology. B6-into-BALB/c BMT was performed (850 cGy host irra-
diation). Cohorts received donor marrow (‘‘BMT’’); marrow and TS/A tumor cells (‘‘TSA’’); marrow, tumor cells, and donor T cells (‘‘GVHD’’);
marrow, tumor cells, donor T cells, and donor-type APC (‘‘GVHD 1 Donor DC’’); or marrow, tumor cells, donor T cells and host-type APC
(‘‘GVHD1HostDC’’). Other cohorts receivedmarrow, tumor cells, donorT cells, and donorTh2 cells either alone (‘‘Th2’’; day 14 post-BMT),
with donor-type APC (‘‘Th21Donor DC’’), or with host-type APC (‘‘Th21Host DC’’). On day 19 post-BMT, lungs from treatment cohorts
were removed to evaluate tumor burden; liver, stomach, small intestine, large intestine, cecum, and skin were harvested to assess GVHD. (A) For
GVHD, each organ was scored (scale5 0 to 4), with cumulativeGVHD score shown (maximum value5 24). (B) For tumor burden, a semiquan-
titative determination of tumor cell infiltration was scored (scale 5 0 to 4); n 5 5 subjects were evaluated per cohort.reduce the number of post-BMT CD41 T cells ema-
nating from the initial allograft (Figure 6b); coinfusion
of donor- or host-type APC did not greatly alter CD4
cell counts post-BMT.
Third, consistent with our previous results, we ob-
served that Th2 cell therapy significantly reduced the
post-BMT number of donor CD81 T cells relative
to GVHD controls (Figure 6a; median values reduced
from 12.4 to 4.1  106 cells/spleen, P 5 .0010). Th2
cell-mediated restriction of CD81 T cell expansion
was partially reversed by host-type, but not donor-
type, APC administration (Figure 6a; increase in
median CD8 number from 4.1 to 7.2  106 cells/
spleen, P5 .0048). Host- or donor-type APC infusion
did not significantly alter post-BMT CD81 T cells
numbers in the absence of Th2 cell infusion.
DISCUSSION
We have previously determined that delayed infu-
sion of donor Th2 cells represent one approach to im-
prove the problematic dissection of GVT effects from
GVHD [7]. This sequential allogeneic immunother-
apy strategy first allows for a Th1/Tc1-mediated
GVT effect, with subsequent downregulation of
GVHD by Th2 cell infusion. In this report, we haveconfirmed that Th2 cells can rapidly downregulate
severe, established GVHD in the setting of fully
MHC-disparate transplantation; the pace of Th2 cell
amelioration of GVHD was relatively rapid, as signif-
icant reversal of histologically definedGVHDwas ob-
served within 5 days of Th2 cell infusion. Of note, the
model that we have utilized is relatively stringent, as
Th2 cell therapy was administered at day 14 posttrans-
plant during GVHD-related cohort lethality. It is
important to note that Th2 cells only resulted in a sur-
vival prolongation without a survival advantage; in an
attempt to demonstrate a Th2 cell survival advantage,
subsequent experiments will utilize lower donor T cell
doses relative to the doses used in the current experi-
ments. Prior investigations into the role of cell therapy
for treatment of establishedGVHDhave been limited,
and in such cases, have utilized a relatively early cell
infusion, such as day 2 or day 10 post-BMT infusion
of regulatory T cells in models of GVHD and GVL
effects involving transplantation into major or minor
histocompatibility disparate hosts, respectively [37].
Furthermore, we have extended our prior observations
by elucidating cellular and molecular mechanisms
associated with this therapy, thereby adding to the
body of knowledge regarding the role of Th2 cells in
the modulation of GVHD and identifying IL-4 and
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Conditions for Th2 Cell Therapy of Established GVHDIL-10 as molecular mechanisms that contribute to
Th2 cell therapy of GVHD.
Th2 cell infusion during established GVHD
resulted in a relatively dramatic alteration in the
Th1/Th2 cytokine balance post-BMT that was char-
acterized by a marked reduction in allospecific IFN-
g secretion and a concomitant increase in allospecific
IL-4 and IL-10 secretion. The experiment we per-
formed usingTh2 cells from cytokine-deficient donors
demonstrated that type II cytokines were indeed the
drivers for the protective effect: that is, recipients of
Th2 cells deficient in either IL-4 or IL-10 had
a post-BMT increase in allospecific IFN-g, an increase
in GVHD by histology analysis, and reduced post-
BMT survival. We have previously shown that IL-4
secretion from Th2 cells is operative in the prevention
of GVHD [7]; the current results are the first to dem-
onstrate that Th2 cell IL-4 secretion is also involved in
the therapy of established GVHD. Similarly, IL-10
has previously been linked to GVHD prevention
through cytokine therapy [15], regulatory T cell [16]
or mesenchymal stem cell [20] therapy, or through
other donor [17,18] or host [19,38] variables. The cur-
rent results are the first to link IL-10mechanistically to
the therapy of established GVHD in general and to
Th2 cell therapy in specific. It is interesting to note
that Th2 cell deficiency in either IL-4 or IL-10 was
sufficient to prevent the Th2 cell anti-GVHD effect.
Of note, IL-4- or IL-10-deficient Th2 cells each led
to reductions in both IL-4 and IL-10 secretion post-
BMT and an increase in IFN-g secretion post-BMT.
As such, it appears that Th2 cell IL-4 and IL-10 may
operate in an interdependent manner. Further
studies will be required to clarify this biology, which
we hypothesize may involve other cell populations,
for example IL-4 polarization of unmanipulated
donor T cells and IL-10 modulation of host- or do-
nor-type APC. Interestingly, Th2 cell prevention of
donor CD81 T cell expansion occurred in a relatively
IL-4 and IL-10-independent manner, thereby sug-
gesting that Th2 cell regulation of CD8 cell expansion
occurs by an alternative mechanism.
Contrary to our hypothesis, we found that IL-2 ad-
ministration completely inhibited the biological and
clinical effect of Th2 cells in the therapy of established
GVHD. It is important to note that IL-2 infusion in
the setting of the GVHD control cohort increased
GVHD by histology and increased the number of
post-BMT donor CD41 T cells but did not reduce
survival duration, did not increase the number of
post-BMT CD81 T cells, and did not alter the post-
BMT Th1 cytokine profile; in sum, these data suggest
that IL-2 availability was only partially limiting within
the GVHD control cohort. By comparison, IL-2 ad-
ministration reduced Th2 cell expansion post-BMT,
increased expansion of CD41 and CD81 T cells orig-
inating from the initial allograft, increased allospecific
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970 J. E. Foley et al.Figure 6. Host-type APC transfer abrogates Th2 cell therapy: donor T cell tracking. B6-into-BALB/c BMT was performed (850 cGy host ir-
radiation). Cohorts received donormarrow alone (‘‘BMT’’); marrow andTS/A tumor cells (‘‘TSA’’); marrow, tumor cells, and additional donorT
cells (‘‘GVHD’’); marrow, tumor cells, donor T cells, and donor-type APC (‘‘GVHD1Donor DC’’); or marrow, tumor cells, donor T cells and
host-type APC (‘‘GVHD1HostDC’’). Other cohorts receivedmarrow, tumor cells, donorT cells, and donorTh2 cells either alone (‘‘Th2’’; day
14 post-BMT), with donor-typeAPC (‘‘Th21DonorDC’’), or with host-typeAPC (‘‘Th21HostDC’’). On day 19 post-BMT, spleen cells were
isolated and the absolute number of donor CD81T cells (A) and CD41T cells (B) emanating from the initial allograft, and the absolute number
of CD90.11Th2 cells [C] were calculated from flow cytometry data (cells per spleen, 106). Data shown are mean 6 SEM (n 5 5 per cohort).IFN-g secretion while limiting IL-4 and IL-10 secre-
tion, and increased GVHD by histology and survival
time analysis. These findings suggest that in the model
we utilized, IL-2 is not a limiting cytokine for Th2 cell
survival and/or expansion at day 14 posttransplant. In-
deed, our findings are more consistent with a scenario
whereby donor Th2 cells act in part as a ‘‘sink’’ for IL-2
that otherwise promotes effector T cell expansion; this
biology would be consistent with findings that con-
sumption of IL-2 [39] or other common-g chain
signaling cytokines such as IL-7 and IL-15 [40] by reg-
ulatory T cell populations can limit effector T cell ex-
pansion. Previous murine experiments have primarily
associated IL-2 as a cytokine operational in the initial
afferent stages of GVHD [27,41]; our murine findings
are consistent with the clinical conclusion that IL-2
also appears to play a role in the pathogenesis of estab-lished aGVHD [29]. Further studies will be required
to evaluate whether alternative cytokine-based strate-
gies might enhance Th2 cell therapy through pre-
ferential expansion of Th2 cells relative to initial
allograft T cells, such as low-dose IL-2 or administra-
tion of IL-7. Taken together, these data suggest that
Th2 cell therapy in this model may operate not only
through specific molecular pathways (IL-4 and IL-10
secretion) but also through additional, more complex
mechanisms such as limitation of cytokine availability.
In addition, we found that infusion of host-type
APC completely inhibited the biological and clinical
effect of Th2 cells in the therapy of established
GVHD. Importantly, infusion of host-type APC in
the setting of the GVHD control cohorts had a rela-
tively modest effect because only post-BMT IFN-g
secretion was increased (no increase in donor T cell
Conditions for Th2 Cell Therapy of Established GVHD 971numbers post-BMT, no increase in GVHD by histol-
ogy, and no reduction in survival time); infusion of
donor-type APC in the setting of the GVHD control
cohort did not modulate any of these 4 experimental
endpoints. These findings suggest that APC number
and/or function were not particularly limiting factors
for GVHD in the control cohort. In marked contrast,
in the setting of Th2 cell therapy, day 14 post-BMT
administration of host-type APC modulated each of
the 4 experimental endpoints relative to control Th2
cell recipients. That is, host APC infusion: (1) reduced
Th2 cell expansion and increased expansion of CD41
andCD81T cells originating from the initial allograft;
(2) increased allospecific IFN-g secretion while limit-
ing IL-4 and IL-10 secretion; (3) increased GVHD by
histology; and (4) reduced post-BMT survival time. By
comparison to host APC infusion, donor-type APC
were less robust in terms of their capacity to modulate
Th2 cell therapy, as only 2 out of the 4 experimental
endpoints were significantly modulated (survival time
was reduced and Th2 polarization was blunted but
GVHD by histology and donor T cell numbers were
not significantly modulated). These finding are consis-
tent with the conclusion reached by other investigators
that both direct and indirect pathways of antigen pre-
sentation contribute to established murine GVHD
[42,43]; in our model using Th2 cell therapy, host-
type APC appear to have played a dominant role. As
such, contrary to our hypothesis, Th2 cell therapy
was not optimized through the provision of additional
alloantigen during established GVHD. Rather, our
results are consistent with the notion that Th2 cells
might ameliorate established GVHD through APC
modulation, in particular, host-type APC modulation.
Because IL-10 was required for Th2 cell efficacy, we
speculate that Th2 cells may have inhibited established
GVHD through the well-characterized ability of IL-
10 to inhibit APC function (reviewed in [44]), with
subsequent reduction in the expansion and activation
of allograft T cells.
In conclusion, these experiments provide further
support to the characterization of acute GVHD as pre-
dominately a Th1/Tc1-type process that is amenable
to regulation by cell therapy with ex vivo generated
donor Th2 cells. To our knowledge, Th2 cell donor
lymphocyte infusion is the only form of adoptive im-
munotherapy identified as being effective in ameliorat-
ing established GVHD at a phase of severe tissue
damage and cohort lethality. This therapeutic effect
required cell product secretion of IL-4 and IL-10,
thereby providing a mechanistic signature that is clas-
sical for a Th2-type response. Our attempts to enhance
Th2 cell therapy with IL-2 administration or APC in-
fusion proved counterproductive; indeed, these failed
therapeutic attempts suggest that the mechanism of
Th2 cell amelioration of established GVHD likely
involve additional components, including cytokineconsumption and APC modulation. As such, further
research will seek to identify alternative strategies to
achieve more profound type IŁ type II cytokine po-
larization in vivo for potential consolidation of Th2
cell-mediated anti-GVHD effects.
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